Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tsumura to File NDA for Daikenchuto in US in 2016
December 7, 2009
- Combined Sales of 21 JPMA Member Companies Up 1.6%
November 30, 2009
- 68% of Prescriptions Permit Generic Substitution, But 88% of Them Not Filled with Generics: Survey
November 30, 2009
- Sato Pharm. Launches Switch OTC Version of Vidarabine
November 30, 2009
- Otsuka HD: Pharma Division Sales Total ¥357.5 Bil.
November 30, 2009
- Market for Generics to Expand to ¥447.9 Bil. in 2011: Fuji Keizai
November 30, 2009
- Kobayashi Pharm.: Sales Up 4.9% due to Influenza Pandemic
November 30, 2009
- Kaken Licenses bFGF to Olympus in Europe, North America
November 30, 2009
- Generics Dispensing Rate Has No Clear Effects on Pharmacies' Business
November 30, 2009
- Adverse Reactions Reported due to GSK's Flu Vaccine
November 30, 2009
- Zeria Aims at 50% Market Share for Asacol: President Ibe
November 30, 2009
- NDA for Liraglutide, Vildagliptin to Be Reviewed
November 30, 2009
- JDS to Include HbA1c in Its Diagnostic Criteria
November 30, 2009
- Sciele Pharma to Acquire Addrenex: Shionogi
November 30, 2009
- JPMA President Stresses the Need for Price Maintenance System
November 30, 2009
- Rohto Posts Record-High Sales Driven by Cosmetic Business
November 30, 2009
- Blopress Japan's Best-Selling Drug in 2nd Qtr: IMS Japan
November 30, 2009
- FJPWA President Expresses Great Concern about GRU WG's Recommendation
November 30, 2009
- JSA Revises Its GL on Prevention and Management of Asthma
November 30, 2009
- Growth of CRO Business Slows Down due to Megamergers: Mr Nakamura
November 30, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…